- Positions
- 29
- Reported value
- $470.4M
- Opened
- 15
- Closed
- 12
- Other managers included
- 0
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
Quarters on file
- Mar 31, 2026$466.5M26 positions
- Jun 30, 2026$470.4M29 positions
What Jones Hill Capital LP reported holding on Form 13F for the quarter ended Jun 30, 2026.
CIK 2102314 · Filed Aug 13, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 1.1M |
| New |
| $28.6M |
| 6.1% |
MDGLMadrigal Pharmaceuticals, Inc. | 52.5K | New | $28.2M | 6% |
BCAXBicara Therapeutics Inc. | 892.6K | −29.2% | $26.5M | 5.6% |
RLMDRelmada Therapeutics, Inc. | 3.7M | +966.4% | $25.3M | 5.4% |
TRVITrevi Therapeutics, Inc. | 1.3M | +261.8% | $25M | 5.3% |
PHVSPharvaris N.V. | 677.9K | +305.9% | $23.4M | 5% |
XENEXenon Pharmaceuticals Inc. | 367.9K | New | $22.2M | 4.7% |
ANIPANI Pharmaceuticals Inc | 233.8K | −26.6% | $19.4M | 4.1% |
IMCRImmunocore Holdings plc | 512.9K | New | $16.3M | 3.5% |
AMLXAmylyx Pharmaceuticals, Inc. | 894.1K | −44.1% | $16.1M | 3.4% |
INSMINSMED Inc | 122.4K | New | $13M | 2.8% |
NUVLNuvalent, Inc. | 98.4K | −67.3% | $12.2M | 2.6% |
CAPRCapricor Therapeutics, Inc. | 420.8K | −53.7% | $10.1M | 2.2% |
ACRSAclaris Therapeutics, Inc. | 1.8M | New | $9.3M | 2% |
IMUXImmunic, Inc. | 539.8K | New | $8.3M | 1.8% |
ORICOric Pharmaceuticals, Inc. | 747.3K | New | $8.1M | 1.7% |
TNXPTonix Pharmaceuticals Holding Corp. | 625.4K | +38.3% | $8M | 1.7% |
SNDXSyndax Pharmaceuticals Inc | 340K | New | $7.4M | 1.6% |
OLMAOlema Pharmaceuticals, Inc. | 574.2K | New | $7.2M | 1.5% |
VIRVir Biotechnology, Inc. | 659.2K | −45.0% | $6.7M | 1.4% |
CRBPCorbus Pharmaceuticals Holdings, Inc. | 653.6K | New | $6.1M | 1.3% |
DNTHDianthus Therapeutics, Inc. | 57.1K | New | $5.6M | 1.2% |
VRTXVertex Pharmaceuticals Inc | 11.1K | −89.8% | $5.5M | 1.2% |
ELVNEnliven Therapeutics, Inc. | 49.9K | −91.6% | $2.5M | 0.5% |
GPCRStructure Therapeutics Inc. | 40.6K | −59.7% | $2.2M | 0.5% |
PHATPhathom Pharmaceuticals, Inc. | 161.5K | New | $1.8M | 0.4% |
ACHVAchieve Life Sciences, Inc. | 26.8K | New | $174.7K | 0.1% |
